anti-HER2 antibody-drug conjugate THIOMAB/Dolasynthen (Mersana Therapeutics/Genentech)

N/A

ๆŠฅๅ‘Šๆ—ถ้—ด: 2025/01/26 19:00:38

ๅŸบๆœฌไฟกๆฏ

่ฏ็‰ฉๅ็งฐanti-HER2 antibody-drug conjugate THIOMAB/Dolasynthen (Mersana Therapeutics/Genentech)
่ฏ็‰ฉๅˆซ็งฐtrastuzumab-based ADC THIOMAB/Dolasynthen (Mersana Therapeutics/Genentech)
่ฏ็‰ฉ็ฑปๅž‹็”Ÿ็‰ฉ่ฏ > ่›‹็™ฝ็ฑป่ฏ็‰ฉ > ๅ…็–ซ็ƒ่›‹็™ฝ > ๆŠ—ไฝ“ > ๆŠ—ไฝ“็ผ€ๅˆ็‰ฉ > ๅ•ๅ…‹้š†ๆŠ—ไฝ“็ผ€ๅˆ็‰ฉ็”Ÿ็‰ฉ่ฏ > ่›‹็™ฝ็ฑป่ฏ็‰ฉ > ๅ…็–ซ็ƒ่›‹็™ฝ > ๆŠ—ไฝ“ > ๅ•ๅ…‹้š†ๆŠ—ไฝ“ > ๅ•ๅ…‹้š†ๆŠ—ไฝ“็ผ€ๅˆ็‰ฉ็”Ÿ็‰ฉ่ฏ > ่›‹็™ฝ็ฑป่ฏ็‰ฉ > ๅ…็–ซ็ƒ่›‹็™ฝ > ๆŠ—ไฝ“ > ๆŠ—ไฝ“็ผ€ๅˆ็‰ฉ > ๆŠ—ไฝ“ๅถ่”่ฏ็‰ฉ๏ผˆADC๏ผ‰
ไฝœ็”จๆœบๅˆถๅ—ไฝ“่›‹็™ฝ้…ชๆฐจ้…ธๆฟ€้…ถ erbB-2ๆ‹ฎๆŠ—ๅ‰‚
้ถ็‚นๅ—ไฝ“่›‹็™ฝ้…ชๆฐจ้…ธๆฟ€้…ถ erbB-2
ๆฒป็–—้ข†ๅŸŸ / ้€‚ๅบ”็—‡่‚ฟ็˜ค
ๅ…จ็ƒๆ‰นๅ‡†้€‚ๅบ”็—‡N/A
ไธญๅ›ฝๆ‰นๅ‡†้€‚ๅบ”็—‡N/A
้ฆ–ๆ‰นๅ›ฝๅฎถ/ๅŒบๅŸŸN/A
้ฆ–ๆ‰นๆ—ฅๆœŸN/A
ๅ›ฝๅฎถ/ๅŒบๅŸŸ็พŽๅ›ฝ
ๆ˜ฏๅฆๅคๆ–นๅฆ
ๅ…จ็ƒๆœ€้ซ˜็ ”ๅ‘็Šถๆ€ไธดๅบŠๅ‰
ไธญๅ›ฝๆœ€้ซ˜็ ”ๅ‘็Šถๆ€N/A
ๅŽŸ็ ”ๅ…ฌๅธMersana Therapeutics Inc
ๆณจๅ†Œๅˆ†็ฑปN/A

็ ”ๅ‘ไฟกๆฏ

ๆดป่ทƒๅ…ฌๅธGenetec IncMersana Therapeutics Inc
้žๆดป่ทƒๅ…ฌๅธN/A
ๆดป่ทƒ้€‚ๅบ”็—‡่‚ฟ็˜ค
้žๆดป่ทƒ้€‚ๅบ”็—‡N/A

ๅ…ถไป–ไฟกๆฏ

ATCไปฃ็ N/A
็›ธๅ…ณ้“พๆŽฅN/A